New hope for elderly lymphoma patients as trial tests powerful three-drug combo
NCT ID NCT07415980
Summary
This study is testing whether a combination of three drugs (polatuzumab vedotin, rituximab, and chidamide) is safe and effective for elderly patients with a specific aggressive type of lymphoma who haven't had treatment before. The first part of the study will determine the safest dose, and the second part will measure how well the treatment works to eliminate the cancer. The trial is specifically for patients aged 70+ (or 60-69 with frailty) who have 'double-expressor' lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE EXPRESSOR DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.